Bedrock Therapeutics, Inc.
Raleigh, NC Doing business as Bedrock Therapeutics Inc.
- UEI
- SB2ZXJBQ4SX3
- CAGE
- 82SX8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 8628 Valley Brook Dr, Raleigh, NC 27613, USA
- Website
- bedrocktherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Intramuscular administration of AAV vectors encoding soluble PD-L1 for rheumatoid arthritis treatment - rheumatoid… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $1 | |
| Vector mediated anti-vascular and anti-inflammatory therapy for AMD - abstract bedrock therapeutics, INC., is developing… | National Eye Institute | $310,952 | |
| Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion - adeno-associated… | National Institute of Diabetes and Digestive and Kidney Diseases | $522,160 | |
| Immunosuppressive gene therapy for ocular graft VS host disease - abstract bedrock therapeutics, INC., is developing a… | National Eye Institute | $984,450 | |
| Prevention of corneal transplant rejection using AAV-bdrk-401 therapy - project description corneal blindness is one… | National Eye Institute | $1,769,317 |
About Bedrock Therapeutics, Inc.
Bedrock Therapeutics, Inc. is a biotechnology company registered in SAM.gov since March 2018, located in Raleigh, North Carolina. The company is a self-certified small disadvantaged business and for-profit organization focused on developing advanced gene therapy solutions using adeno-associated virus (AAV) vector technologies. Bedrock Therapeutics specializes in developing innovative therapeutic approaches for various medical conditions, with a primary emphasis on creating targeted gene therapies that address complex inflammatory and immunological disorders.
The company has secured multiple federal grant awards from prestigious national institutes, including the National Institute of Allergy and Infectious Diseases, National Eye Institute, and National Institute of Diabetes and Digestive and Kidney Diseases. These grants, totaling approximately $615,453, support cutting-edge research in developing gene therapies for conditions such as rheumatoid arthritis, neovascular age-related macular degeneration, ocular graft versus host disease, and liver-targeted gene therapy. Bedrock's research focuses on leveraging AAV vector delivery systems to introduce therapeutic proteins that modulate immune responses, reduce inflammation, and potentially provide long-term treatment solutions for challenging medical conditions. Their innovative approaches include developing soluble PD-L1 therapies for rheumatoid arthritis, single-chain immunomodulating proteins for macular degeneration, and novel AAV vectors with enhanced human hepatocyte tropism and neutralizing antibody evasion capabilities.
Quick answers
What is Bedrock Therapeutics, Inc.'s UEI?
Bedrock Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is SB2ZXJBQ4SX3.
What is Bedrock Therapeutics, Inc.'s CAGE code?
Bedrock Therapeutics, Inc.'s CAGE code is 82SX8.
What is Bedrock Therapeutics, Inc.'s primary NAICS code?
Bedrock Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Bedrock Therapeutics, Inc. located?
Bedrock Therapeutics, Inc.'s physical address in SAM.gov is 8628 Valley Brook Dr, Raleigh, NC 27613, USA.
Is Bedrock Therapeutics, Inc. registered in SAM.gov?
Yes. Bedrock Therapeutics, Inc.'s SAM.gov registration is active through July 13, 2027.
What is Bedrock Therapeutics, Inc.'s most recent federal award?
Bedrock Therapeutics, Inc.'s most recent federal grant award is Intramuscular administration of AAV vectors encoding soluble PD-L1 for rheumatoid arthritis treatment - rheumatoid… (R41AR086050), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on September 19, 2025.
On GovTribe
See Bedrock Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors